Get the Stockscreener App
12.96
2.94%
0.37
After Hours:
12.96
Gh Research Plc stock is traded at $12.96, with a volume of 242.51K.
It is up +2.94% in the last 24 hours and up +8.54% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$12.59
Open:
$13.15
24h Volume:
242.51K
Relative Volume:
0.87
Market Cap:
$674.28M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-16.41
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
-0.77%
1M Performance:
+8.54%
6M Performance:
+44.00%
1Y Performance:
+88.65%
1-Day Range:
$12.68
$13.15
1-Week Range:
$12.26
$13.65
52-Week Range:
$6.72
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
12.96 | 780.95M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
Depression-Focused GH Research Shares Could See Significant Upside: Analyst - Benzinga
Real time alert setup for GH Research PLC performanceTrade Ideas & Weekly Hot Stock Watchlists - newser.com
Is GH Research PLC stock a buy in volatile marketsQuarterly Market Review & Technical Confirmation Alerts - newser.com
Is GH Research PLC stock cheap at current valuationDay Trade & AI Driven Stock Price Forecasts - newser.com
Is GH Research PLC stock attractive for income investorsJuly 2025 Patterns & Weekly Top Stock Performers List - newser.com
Combining machine learning predictions for GH Research PLCJuly 2025 Levels & Proven Capital Preservation Tips - newser.com
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Is GH Research PLC stock a safe buy before earnings2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
How GH Research PLC stock responds to policy changesWeekly Stock Report & High Accuracy Swing Entry Alerts - newser.com
Signal strength of GH Research PLC stock in tech scannersMarket Risk Report & Verified Short-Term Plans - newser.com
GH Research Presents Promising GH001 Trial Data at ECNP 2025 - TipRanks
Can a trend reversal in GH Research PLC lead to recoveryRisk Management & Risk Managed Trade Strategies - newser.com
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress - GlobeNewswire
GH Research PLC stock momentum explainedMarket Sentiment Report & Free Daily Entry Point Trade Alerts - newser.com
GH Research Showcases Promising Depression Treatment at ECNP 2025 - TipRanks
GH Research PLC Announces Acceptance of Presentation and Posters on GH001 for Treatment-Resistant Depression at ECNP Congress - Quiver Quantitative
No treatment-related SAEs: GH Research 6‑Month GH001 safety & psychoactive data for TRD at ECNP 2025 - Stock Titan
Will GH Research PLC stock outperform international peers2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Using fundamentals and technicals on GH Research PLCJuly 2025 Action & Weekly High Potential Alerts - newser.com
GH Research's (GHRS) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Market reaction to GH Research PLC’s recent newsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Can volume confirm reversal in GH Research PLCQuarterly Risk Review & High Win Rate Trade Alerts - newser.com
Has GH Research PLC found a price floorJuly 2025 Summary & Real-Time Volume Analysis Alerts - newser.com
Does GH Research PLC qualify in momentum factor screeningMarket Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Will GH Research PLC stock benefit from automationWall Street Watch & Low Drawdown Investment Ideas - newser.com
Why millennials buy GH Research PLC (1KA) stockJuly 2025 Fed Impact & AI Driven Price Forecasts - newser.com
What drives GH Research PLC 1KA stock priceMonthly Performance Summary & Free Smart Trading Classes - earlytimes.in
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):